Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares shot up 1.8% during trading on Friday . The stock traded as high as $39.74 and last traded at $39.61, with a volume of 155,899 shares. The stock had previously closed at $38.90.

Several research firms have commented on ITCI. Zacks Investment Research cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. Leerink Swann reiterated a “buy” rating on shares of Intra-Cellular Therapies in a report on Thursday, June 30th. Cowen and Company reiterated a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, June 29th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $57.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, June 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $70.78.

The company’s market capitalization is $1.71 billion. The firm has a 50 day moving average of $38.97 and a 200 day moving average of $35.48.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.14. Analysts expect that Intra-Cellular Therapies Inc. will post ($3.14) earnings per share for the current fiscal year.

A number of hedge funds and institutional investors have bought and sold shares of ITCI. Jennison Associates LLC raised its position in Intra-Cellular Therapies by 212.9% in the fourth quarter. Jennison Associates LLC now owns 1,257,846 shares of the biopharmaceutical company’s stock valued at $67,660,000 after buying an additional 855,846 shares during the last quarter. Marshall Wace LLP raised its position in Intra-Cellular Therapies by 23.5% in the fourth quarter. Marshall Wace LLP now owns 23,148 shares of the biopharmaceutical company’s stock valued at $1,245,000 after buying an additional 4,410 shares during the last quarter. Tekla Capital Management LLC raised its position in Intra-Cellular Therapies by 25.2% in the fourth quarter. Tekla Capital Management LLC now owns 187,800 shares of the biopharmaceutical company’s stock valued at $10,102,000 after buying an additional 37,800 shares during the last quarter. New York State Common Retirement Fund raised its position in Intra-Cellular Therapies by 27.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,600 shares of the biopharmaceutical company’s stock valued at $1,431,000 after buying an additional 5,800 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Intra-Cellular Therapies by 505.4% in the fourth quarter. California Public Employees Retirement System now owns 78,700 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 65,700 shares during the last quarter.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.